Q4 2018 EPS Estimates for Gilead Sciences, Inc. Raised by William Blair (GILD)

Gilead Sciences, Inc. (NASDAQ:GILD) – Equities research analysts at William Blair lifted their Q4 2018 earnings per share estimates for Gilead Sciences in a research note issued on Wednesday. William Blair analyst Y. Xu now forecasts that the biopharmaceutical company will post earnings of $1.88 per share for the quarter, up from their prior forecast of $1.78. William Blair currently has a “Buy” rating on the stock.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.67 by $0.11. The company had revenue of $5.95 billion for the quarter, compared to analyst estimates of $5.71 billion. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. Gilead Sciences’s revenue for the quarter was down 18.7% compared to the same quarter last year. During the same quarter last year, the company earned $2.70 EPS.

A number of other equities research analysts have also issued reports on GILD. Zacks Investment Research lowered Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Wednesday, October 18th. Berenberg Bank set a $96.00 price objective on Gilead Sciences and gave the company a “buy” rating in a report on Thursday, October 19th. Leerink Swann increased their price objective on Gilead Sciences from $84.00 to $85.00 and gave the company a “market perform” rating in a report on Thursday, October 19th. Maxim Group reiterated a “hold” rating on shares of Gilead Sciences in a report on Thursday, October 19th. Finally, BMO Capital Markets reiterated a “hold” rating and issued a $82.00 price objective on shares of Gilead Sciences in a report on Friday, October 20th. One analyst has rated the stock with a sell rating, twelve have issued a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $87.04.

Shares of Gilead Sciences (GILD) opened at $79.32 on Monday. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.55 and a quick ratio of 3.48. The stock has a market capitalization of $103,613.26, a PE ratio of 22.79, a price-to-earnings-growth ratio of -1.77 and a beta of 1.22. Gilead Sciences has a 12-month low of $63.76 and a 12-month high of $89.54.

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 29th. Shareholders of record on Friday, March 16th will be paid a $0.57 dividend. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.52. This represents a $2.28 annualized dividend and a dividend yield of 2.87%. The ex-dividend date is Thursday, March 15th. Gilead Sciences’s dividend payout ratio (DPR) is 59.77%.

In other Gilead Sciences news, insider John C. Martin sold 50,000 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $73.62, for a total value of $3,681,000.00. Following the transaction, the insider now directly owns 3,046,766 shares in the company, valued at approximately $224,302,912.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Gregg H. Alton sold 15,000 shares of Gilead Sciences stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $74.64, for a total value of $1,119,600.00. Following the completion of the transaction, the executive vice president now owns 70,988 shares in the company, valued at $5,298,544.32. The disclosure for this sale can be found here. Insiders sold a total of 358,333 shares of company stock worth $28,066,908 over the last quarter. Company insiders own 1.30% of the company’s stock.

Several hedge funds have recently made changes to their positions in the business. Keel Point LLC lifted its holdings in shares of Gilead Sciences by 0.4% in the 2nd quarter. Keel Point LLC now owns 3,123 shares of the biopharmaceutical company’s stock valued at $221,000 after buying an additional 12 shares during the period. Paradigm Financial Advisors LLC lifted its holdings in shares of Gilead Sciences by 0.3% in the 2nd quarter. Paradigm Financial Advisors LLC now owns 8,723 shares of the biopharmaceutical company’s stock valued at $617,000 after buying an additional 26 shares during the period. Princeton Portfolio Strategies Group LLC lifted its holdings in shares of Gilead Sciences by 0.4% in the 2nd quarter. Princeton Portfolio Strategies Group LLC now owns 9,766 shares of the biopharmaceutical company’s stock valued at $691,000 after buying an additional 41 shares during the period. Auxier Asset Management lifted its holdings in shares of Gilead Sciences by 1.4% in the 2nd quarter. Auxier Asset Management now owns 6,773 shares of the biopharmaceutical company’s stock valued at $479,000 after buying an additional 96 shares during the period. Finally, Edmonds Duncan Registered Investment Advisors LLC lifted its holdings in shares of Gilead Sciences by 1.6% in the 2nd quarter. Edmonds Duncan Registered Investment Advisors LLC now owns 6,386 shares of the biopharmaceutical company’s stock valued at $452,000 after buying an additional 100 shares during the period. Institutional investors own 76.47% of the company’s stock.

WARNING: This article was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another publication, it was illegally copied and republished in violation of US & international copyright & trademark law. The original version of this article can be viewed at https://www.americanbankingnews.com/2018/02/12/q4-2018-eps-estimates-for-gilead-sciences-inc-raised-by-william-blair-gild.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Earnings History and Estimates for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply